

# | EDUCATIONAL PROGRAMME

This information is valid up to 13 May 2011.  
Visit [www.erscongress2011.org](http://www.erscongress2011.org) for updates.

# EDUCATIONAL PROGRAMME OVERVIEW

## POSTGRADUATE COURSES

### Saturday 24 September 2011 | 09:30-13:00

- PG1 Interventional Pulmonology
- PG2 Noninvasive ventilation for stable hypercapnic COPD: recent advances and practical considerations
- PG3 Workshop: Genomics and proteomics of lung disease
- PG4 Functional lung imaging to describe regional lung function disturbances
- PG5 Asthma *versus* COPD: similarities and differences
- PG6 Paediatric asthma: state of the art
- PG7 An update on pleural problems
- PG8 Assessing respiratory muscle strength: an interactive course
- PG9 Risk stratification and treatment of lower respiratory tract infections
- PG10 Management of thoracic tumors in practice: a HERMES basic course

### Saturday 24 September 2011 | 014:00-17:30

- PG11 Update of phenotypes of asthma and COPD
- PG12 Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management
- PG13 ERS/ACCP jointly organised: evidence-based approach to advanced respiratory care
- PG14 Improving skills in cardiopulmonary exercise testing
- PG15 Treatment of obstructive sleep apnoea
- PG16 Thoracic ultrasound for physicians
- PG17 Emerging infections: educational perspectives
- PG18 Early detection of COPD: benefits and problems
- PG19 How to set up and deliver a smoking cessation service in a pulmonology department
- PG20 Biomarkers in respiratory medicine

## EARLY MORNING SEMINARS

### Monday 26 September 2011 | 07:00-08:15

- EM1 Extending bronchial challenge testing in the lab
- EM2 Interpretation of sleep studies: problem areas

### Tuesday 27 September 2011 | 07:00-08:15

- EM3 Assessing efficiency of mechanical ventilation: secrets of success
- EM4 Interpreting high-resolution computed tomography scans: top tips

## "MEET THE PROFESSOR" SEMINARS

### Sunday 25 September 2011 | 13:00-14:00

- MP1 Rehabilitation as part of lung cancer management?  
*M. A. Spruit (Horn, The Netherlands)*
- MP2 Lung ultrasound in critically ill patients  
*J. Rouby (Paris, France)*
- MP3 Mild COPD: what's all the fuss?  
*D. Marciniuk (Saskatoon, Canada)*
- MP4 How to select OSA patients for upper airway interventions  
*W. De Backer (Antwerp, Belgium)*
- MP5 Management of severe asthma  
*G. Brusselle (Ghent, Belgium)*
- MP6 Primary ciliary dyskinesia: current state of the art  
*C. O Callaghan (Leicester, United Kingdom)*

### Monday 26 September 2011 | 13:00-14:00

- MP7 Is the increase in asthma prevalence over in Europe? And worldwide?  
*B. Lundback (Gothenburg, Sweden)*
- MP8 Post-transplant infections: diagnosis and treatment  
*C. Chaparro (Toronto, Canada)*
- MP9  $\beta$ -blockers in respiratory medicine  
*N. Hanania (Houston, United States of America)*
- MP10 Antibiotic treatment of exacerbations of COPD: when, why... and how?  
*S. Sethi (Buffalo, United States of America)*
- MP11 What is the optimal lymph node staging algorithm in locoregional nonsmall-cell lung cancer? PRO/CON DEBATE  
*G. Massard (Strasbourg, France), J. Annema (Leiden, The Netherlands)*
- MP12 Strategies for treating idiopathic pulmonary fibrosis  
*R.M. Du Bois (London, United Kingdom)*

### Tuesday 27 September 2011 | 13:00-14:00

- MP13 Cardiovascular disease in asthma and COPD  
*M. Cazzola (Rome, Italy)*
- MP14 Adenosine receptors and asthma  
*C. Page (London, United Kingdom)*
- MP15 Long-term weaning: nursing challenges  
*D. Field (London, United Kingdom)*
- MP16 Pre-operative pulmonary assessment  
*C. Bolliger (Cape Town, South Africa)*
- MP17 All that wheezes is not asthma  
*K. Guntupalli (Houston, United States of America)*
- MP18 Regulation of immune tolerance in the lung  
*C. Hawrylowicz (London, United Kingdom)*

## | EDUCATIONAL PROGRAMME

This information is valid up to 13 May 2011.  
Visit [www.erscongress2011.org](http://www.erscongress2011.org) for updates.

SATURDAY  
24

9:30 - 13:00

**PG1 Postgraduate Course: Interventional Pulmonology**

**Aims:** To define the role of the main diagnostic and therapeutic interventional procedures in the management of lung cancer, and of other lung and pleural diseases. At the end of this Course, participants will know the technical aspects of the procedures and how to include them in the appropriate clinical setting.



**HERMES syllabus links:** D.2.11 Flexible bronchoscopy, D.2.17 Rigid bronchoscopy, D.2.18 Interventional bronchoscopic techniques including fluorescence bronchoscopy, brachytherapy, endobronchial radiotherapy, afterloading laser and electrocoagulation cryotherapy, photodynamic therapy, airway stents, D.2.14 Endobronchial ultrasound, D.2.10 Pleuroscopy (medical thoracoscopy), D.2.13 Transbronchial needle aspiration.

**Type of course:** Case- and problem-based.

**Target audience:** Respiratory physicians, critical care physicians, thoracic surgeons, trainees, thoracic oncologists.

**Chairs:** T. Sutedja (Amsterdam, The Netherlands), C. Dooms (Leuven, Belgium)

09:30 Sampling techniques in bronchoscopy. Is there any news?

R. Eberhardt (Heidelberg, Germany)

10:15 Histology *versus* cytology: is it the true problem? What the pathologists are asking to interventional pulmonology

A. Orlandi (Roma, Italy)

11:00 Break

11:30 Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers

J. Vergnon (Saint-Etienne, France)

12:15 Transbronchial needle aspiration (TBNA) and endobronchial ultrasound-TBNA: not only lung cancer staging

R. Trisolini (Bologna, Italy)

9:30 - 13:00

**PG2 Postgraduate Course: Noninvasive ventilation for stable hypercapnic COPD: recent advances and practical considerations**

**Aims:** To update participants on recent advances in the application of long-term noninvasive ventilation (NIV) in stable hypercapnic chronic obstructive pulmonary disease (COPD) patients and to provide practical considerations for daily clinical use.



**HERMES syllabus links:** A.1 Structure and function of the respiratory system, B.9 Acute injury, B.10 Respiratory failure, B.15 Genetic and developmental disorders, E.1.18 Principles of stem cell therapy, E.1.6 Ventilatory support, G.1 Intensive care, G.2 High-dependency unit, H.1 Thoracic surgery, I.4 Quality of life measures.

**Type of course:** Case- and problem-based.

**Target audience:** Pulmonologists, emergency medicine doctors, respiratory physicians, clinical researchers, general practitioners, research fellows.

**Chairs:** E. Clini (Modena, Italy), P. Navalesi (Vercelli, Italy)

09:30 How to apply the new concept of high-intensity NIV

W. Windisch (Freiburg, Germany)

10:15 Clinical decision making: when to start long-term NIV following acute exacerbation

M. W. Elliott (Leeds, United Kingdom)

11:00 Break

11:30 Techniques of NIV used during physical activity and rehabilitation

P. Wijkstra (Groningen, The Netherlands)

12:15 How to deal with end of life issues

M. Vitacca (Lumezzane, Italy)

9:30 - 13:00

**PG3 Postgraduate Course: Workshop: Genomics and proteomics of lung disease**

**Aims:** To introduce novel techniques of genomics and proteomics and present the potential of these methods in basic and disease-related lung research, and clinical practice.



**HERMES syllabus links:** A.1.3 Physiology, A.1.6 Genetics, A.1.8 Pathology, B.2.1 Lung cancer, B.1 Airway diseases, B.7 Diffuse parenchymal (interstitial) lung diseases.

**Type of course:** Workshop

**Target audience:** Pulmonologists, emergency medicine doctors, respiratory physicians, clinical researchers, research fellows, basic scientists, intensivists, pathologists, allergologists, trainees.

**Chairs:** Chair to be confirmed, P. Hiemstra (Leiden, The Netherlands)

09:30 Genome-wide approaches to lung cancer

Speaker to be confirmed

- 10:15 Genomics and system biology: where does it take us in the future ?  
Speaker to be confirmed
- 11:00 Break
- 11:30 Proteomics approach in lung disease: the magic tool?  
V. Kinnula (Helsinki, Finland)
- 12:15 The challenge of providing proteomic tools in clinical practice  
G. Marko-Varga (Lund, Sweden)

9:30 - 13:00

#### PG4 Postgraduate Course: Functional lung imaging to describe regional lung function disturbances



**Aims:** To overview the status of imaging methods that are suitable for measuring regional lung function.

**HERMES syllabus links:** B.1.4 COPD (chronic obstructive bronchitis and/or emphysema), A.1.4 Pathophysiology, B.1.1 Asthma.

**Type of course:** Lecture- and case-based.

**Target audience:** Respiratory physicians, clinical researchers, physiologists.

**Chairs:** W. De Backer (Antwerp, Belgium), G. Miserocchi (Monza, Italy)

- 09:30 Lung parenchyma density and airway thickness in airway diseases  
H. Coxson (Vancouver, Canada)
- 10:15 Alterations in regional lung ventilation induced by bronchoconstriction: lessons from animal models  
S. Bayat (Amiens, France)
- 11:00 Break
- 11:30 Lung Ultrasound  
J. Rouby (Paris, France)
- 12:15 Airway segmentation and fluid dynamics to describe regional lung function disturbances  
W. De Backer (Antwerp, Belgium)

9:30 - 13:00

#### PG5 Postgraduate Course: Asthma versus COPD: similarities and differences



**Aims:** To discuss the similarities and differences between asthma and COPD.

**HERMES syllabus links:** A.1.4 Pathology, B.1.1 Asthma, A.1.3 Physiology, B.1.4 COPD

**Type of course:** Lecture-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, clinical researchers, general practitioners, research fellows, basic scientists, pathologists, allergologists, trainees.

**Chairs:** P. J. Barnes (London, United Kingdom), R. Dahl (Aarhus, Denmark)

- 09:30 Genetic studies in asthma and COPD: what have we learned?  
G. Brusselle (Ghent, Belgium)
- 10:15 Response to steroids  
P. J. Barnes (London, United Kingdom)
- 11:00 Break
- 11:30 Role of obesity in asthma and COPD  
N. Hanania (Houston, United States of America)
- 12:15 New bronchodilators and inhaled steroids  
M. Cazzola (Rome, Italy)

9:30 - 13:00

#### PG6 Postgraduate Course: Paediatric asthma: state of the art



**Aims:** Asthma is the most prevalent chronic disorder in schoolchildren in the western world, causing considerable morbidity. This PG course aims to provide participants with state-of-the-art knowledge of different topics in paediatric asthma.

**HERMES syllabus links:** B.1.1 Asthma, B.16.1 Asthma, B.17.2 Asthma, H.3 Paediatric respiratory medicine

**Type of course:** Lecture- and evidence-based.

**Target audience:** Pulmonologists, respiratory physicians, clinical researchers, general practitioners, nurses, allergologists, trainees, paediatricians, fellows in paediatric respiratory medicine.

**Chairs:** M. Pijnenburg (Rotterdam, The Netherlands), K. Lødrup Carlsen (Oslo, Norway)

- 09:30 New insights into the pathophysiology of asthma  
G. Roberts (Winchester, United Kingdom)
- 10:15 Respiratory symptoms in the under-fours: asthma or not?  
A. Moeller (Zurich, Switzerland)
- 11:00 Break
- 11:30 Asthma treatment: state of the art.  
B. Rottier (Groningen, The Netherlands)

- 12:15 Difficult-to-treat asthma  
F. De Benedictis (Ancona, Italy)

9:30 - 13:00

### PG7 Postgraduate Course: An update on pleural problems

**Aims:** To update participants knowledge on pleural problems, to orientate the diagnosis and treatment of pleural effusions (complicated or not), pneumothorax, empyema and special post-operative complications after surgical treatment.



**HERMES syllabus links:** B.11 Pleural diseases, D.2.18 Interventional techniques, H.1 Thoracic surgery.

**Type of course:** Lectures, clinical cases and theoretical review.

**Target audience:** Pulmonologists, respiratory physicians, general practitioners, intensivists, nurses, thoracic surgeons, trainees.

**Chairs:** D. Lardinois (Basel, Switzerland), L. Casali (Terni, Italy)

- 09:30 Diagnostic algorithm in fused and nonfused pleural space: when to refer a patient for surgery  
F. Herth (Heidelberg, Germany)
- 10:15 Pleural empyema: still only a surgical problem?  
S. Elia (Rome, Italy)
- 11:00 Break
- 11:30 An update on pleurodesis for pneumothorax and pleural effusions  
E. Canalis (Barcelona, Spain)
- 12:15 Specific pleural problems after surgical treatment  
D. Subotic (Belgrade, Republic of Serbia)

9:30 - 13:00

### PG8 Postgraduate Course: Assessing respiratory muscle strength: an interactive course

**Aims:** To outline the usefulness, availability and limitations of respiratory muscle assessment.



**HERMES syllabus links:** D.1.9 Respiratory muscle assessment – interpretation, A.1 Structure and function of the respiratory system, B.10.3 Neuromuscular disease, B.12.2 Neuromuscular disorders, D.1.7 Assessment of respiratory mechanics – interpretation, H.4 Chest physiotherapy.

**Type of course:** Lecture-based, case- and problem-based, case- and video-based.

**Target audience:** Respiratory physicians/technicians, physiologists, basic scientists, respiratory therapists, nurses, trainees, allied health professionals.

**I. Steenbruggen, Chair to be confirmed.**

- 09:30 The nuts and bolts of respiratory muscle testing  
A. Rossi (Bergamo, Italy)
- 10:15 Volitional assessment of respiratory muscle strength  
J. Fitting (Lausanne, Switzerland)
- 11:00 Break
- 11:30 Nonvolitional measures of respiratory muscle force (clinical and research application)  
M. Polkey (London, United Kingdom)
- 12:15 Integration of respiratory muscle assessment in clinical practice (case reports)  
T. Troosters (Leuven, Belgium)

9:30 - 13:00

### PG9 Postgraduate Course: Risk stratification and treatment of lower respiratory tract infections

**Aims:** To present risk factors for clinical failure. Describe the clinical application of the new markers of poor outcome in different lower respiratory tract infections (LRTIs), such as pneumonia, exacerbations of COPD and bronchiectasis.



**HERMES syllabus links:** B.3.2 Lower respiratory tract infections, B.3.3 Community-acquired pneumonia, D.2.1 Blood tests and serology relevant to respiratory medicine.

**Type of course:** Lecture- and case-based.

**Target audience:** Pulmonologists, emergency medicine doctors, respiratory physicians, clinical researchers, general practitioners, research fellows, intensivists.

**Chairs:** G. Rohde (Maastricht, The Netherlands), A. Torres (Barcelona, Spain)

- 09:30 New challenges in LRTIs: identifying patients at risk for failure  
F. Blasi (Milan, Italy)
- 10:15 Predictors of clinical failure in community acquired pneumonia  
T. Welte (Hannover, Germany)
- 11:00 Break
- 11:30 Risk stratification in bronchiectasis  
R. Wilson (London, United Kingdom)
- 12:15 Implications for the management and treatment of LRTI  
M. Tamm (Basel, Switzerland)

### PG10 Postgraduate Course: Management of thoracic tumors in practice: a HERMES basic course

**Aims:** To cover major parts of the HERMES core syllabus in Thoracic oncology (Module B.2 level 3 mandatory items, as well as E.1.2 and E.1.3 modules regarding treatment modalities). The course is intended to provide basic knowledge to medical practitioners involved in the management of lung cancer patients.



**HERMES syllabus links:** B.2.1 Lung cancer, B.2.3 Mesothelioma, E.1.2 Chemotherapy, E.1.3. Other systemic anti-tumour therapy, H.1. Thoracic surgery (including lung transplantation).

**Type of course:** Lecture- and case-based.

**Target audience:** Respiratory physicians, general practitioners, thoracic oncologists, nurses, trainees, thoracic surgeons.

**Chairs:** J. Vansteenkiste (Leuven, Belgium), N. Schoenfeld (Berlin, Germany)

09:30 Epidemiology, diagnosis, classification and staging of lung cancer  
A.-P. Meert (Brussels, Belgium)

10:15 Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy)  
G. Massard (Strasbourg, France)

11:00 Break

11:30 Treatment strategy for patients with locally advanced and metastatic nonsmall-cell lung cancer  
J. Vansteenkiste (Leuven, Belgium)

12:15 Small-cell lung cancer and mesothelioma: diagnosis and management  
A. Scherpereel (Lille, France)

14:00 - 17:30

### PG11 Postgraduate Course: Update of phenotypes of asthma and COPD

**Aims:** Asthma and COPD are not single disease entities. Both asthma and COPD, particularly COPD, include different clinical phenotypes with different risk factor patterns and clinical presentation, and have large variations in prognosis. New data are continuously presented in high-ranked journals. There is also a new debate about revision of the taxonomy of obstructive airway diseases.



**HERMES syllabus links:** B.1.1 asthma, B.1.4 COPD/emphysema, B.1.3 chronic bronchitis, B.6.1 occupational asthma.

**Type of course:** Case- and problem-based.

**Target audience:** Pulmonologists, respiratory physicians, clinical researchers, general practitioners, allergologists, research fellows.

**Chairs:** E. Ronmark (Lulea, Sweden), R. Polosa (Catania, Italy)

14:00 How to define clinically relevant phenotypes and endotypes of asthma and COPD  
B. Lundback (Gothenburg, Sweden)

14:45 Clinically important phenotypes of severe asthma  
S. Wengel (Pittsburgh, United States of America)

15:30 Break

16:00 Clinically important major phenotypes of COPD  
P. Bakke (Bergen, Norway)

16:45 The role of cluster analysis in defining phenotypes of obstructive airway diseases: is there a need for a new taxonomy of obstructive airway diseases?  
R. Beasley (Wellington, New Zealand)

14:00 - 17:30

### PG12 Postgraduate Course: Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management

**Aims:** To train European physicians on multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) management using standardised materials developed as part of the TB-PANNET Train the Trainer exercise.



**HERMES syllabus links:** B.4 Tuberculosis.

**Type of course:** Case- and problem-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, clinical researchers, general practitioners, research fellows, nurses, thoracic surgeons, trainees.

**Chairs:** C. Lange (Borstel, Germany), G. Bothamley (London, United Kingdom)

14:00 MDR-TB: from epidemiology to treatment design  
J.-P. Zellweger (Fribourg, Switzerland)

14:45 XDR-TB in South Africa: from clinical management to public health action  
K. Dheda (Cape Town, South Africa)

15:30 Break

16:00 Shocking stories of XDR-TB and MDR-TB from the USA  
T. Aksamit (Rochester, United States of America)

16:45 XDR-TB and MDR-TB in Europe: still a challenge  
A. Matteelli (Brescia, Italy)



**PG13 Postgraduate Course: ERS/ACCP jointly organised: evidence-based approach to advanced respiratory care**

**Aims:** To understand the process by which evidence-based guidelines are developed and implemented into practice; to gain practical knowledge for using an evidence-based approach in managing the solitary pulmonary nodule; to learn to apply clinical evidence derived by clinical trials and the experience of real life already present in literature in treating severe asthma and pulmonary hypertension.

**HERMES syllabus links:** F5 Audit/quality assurance of clinical practice, I.3. Evidence-based medicine, B.1.1 Asthma, B.5 Pulmonary vascular diseases.

**Type of course:** Case-, lecture- and problem-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, nurses, trainees.

**Chairs:** N. Siafakas (Heraklion, Greece), A. Sharafkhaneh (Houston, United States of America)

- 14:00 State of the art: development of evidence-based clinical practice guidelines  
D. Guterman (Milwaukee, United States of America)
- 14:45 An evidence-based algorithmic approach to the solitary pulmonary nodule  
S. Rao (Brooklyn, United States of America)
- 15:30 Break
- 16:00 Evidence-based treatments for severe asthma  
P. Chanez (Marseille, France)
- 16:45 Evidence-based treatment algorithm in pulmonary arterial hypertension  
N. Galiè (Bologna, Italy)

**PG14 Postgraduate Course: Improving skills in cardiopulmonary exercise testing**

**Aims:** At the end of the course the participants will know: the usefulness of exercise testing in clinical trials, the interpretation of clinical exercise testing, the state-of-the-art knowledge on the performance and usefulness of inspiratory capacity during exercise, and useful tips in how to measure daily living activity.

**HERMES syllabus links:** D.1.6 Exercise testing including walking tests and spiroergometry – interpretation and performance, E. 1.14 Pulmonary rehabilitation, C.1.1 Dyspnoea, D.1.7 Assessment of respiratory mechanics – interpretation.

**Type of course:** Lecture- and case-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, general practitioners, clinicians with an interest in cardiorespiratory medicine and clinical rehabilitation, exercise physiologists, and respiratory therapists and technicians.

**Chairs:** R. Gosselink (Leuven, Belgium), L. Puente Maestú (Madrid, Spain)

- 14:00 Exercise testing as an outcome  
P. Palange (Rome, Italy)
- 14:45 Case-based guide to cardiopulmonary exercise test interpretation  
B. Whipp (Powys, United Kingdom)
- 15:30 Break
- 16:00 Practical aspects of end-tidal lung volume measurements  
D. O'Donnell (Kingston, Canada)
- 16:45 Clinical measurement of daily living activity  
T. Troosters (Leuven, Belgium)

**PG15 Postgraduate Course: Treatment of obstructive sleep apnoea**

**Aims:** To provide an overview of all available treatment modalities for obstructive sleep apnoea (OSA) and to discuss some of them in detail.

**HERMES syllabus links:** B.19 Sleep-related disorders, B.19.1 obstructive sleep apnoea syndrome.

**Type of course:** Case- and lecture-based.

**Target audience:** Respiratory therapists, respiratory physicians, clinical researchers, general practitioners, otolaryngologist, neurologists, physiologists.

**Chairs:** W. De Backer (Antwerp, Belgium), S. Andreas (Immenhausen, Germany)

- 14:00 Overview of treatment modalities  
R. L. Riha (Edinburgh, United Kingdom)
- 14:45 Continuous positive airway pressure  
W. Randerath (Solingen, Germany)
- 15:30 Break
- 16:00 Non-CPAP therapies  
J-L. Pepin (Grenoble, France)
- 16:45 Treatment of paediatric sleep apnoea  
S. Verhulst (Wilrijk, Belgium)

**PG16 Postgraduate Course: Thoracic ultrasound for physicians**

**Aims:** To understand the basic physics behind ultrasound; to understand how to operate an ultrasound machine and how to get the most from the equipment; to understand the indications, limitations and common pitfalls of thoracic ultrasound, understand the benefits of day to day use on the respiratory ward and obtain the theoretical part of thoracic ultrasound training laid out in the HERMES.



**HERMES syllabus links:** D.3.5 Ultrasound.

**Type of course:** Lecture-, case- and problem-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, intensivists, radiologists, thoracic surgeons, trainees.

**Chairs:** F. Gleeson (Oxford, United Kingdom), N. Maskell (Bristol, United Kingdom)

- 14:00 How to develop a pleural service  
N. Maskell (Bristol, United Kingdom)
- 14:45 Brief overview of the physics of ultrasound and thoracic ultrasound in practice  
F. Gleeson (Oxford, United Kingdom)
- 15:30 Break
- 16:00 Ultrasound equipment familiarisation and thoracic ultrasound in practice  
N. Rahman (Oxford, United Kingdom)
- 16:45 Use of ultrasound in thoracoscopy and chest drains  
G. Tassi (Gussago, Italy)

**PG17 Postgraduate Course: Emerging infections: educational perspectives**

**Aims:** To acquire knowledge on the role of respiratory viruses in the development of atopic disorders, namely allergic rhinitis and asthma, and to learn about signs, symptoms, diagnosis and treatment of respiratory syncytial virus infections in children. Furthermore, to learn which emerging respiratory viruses play a major role, and to acquire an overview on the bacteriological variety in chronic airway diseases.



**HERMES syllabus links:** B.1.1 Asthma, B.1.5 Bronchiolitis, B.3.1 Upper respiratory tract infections, B.3.2 Lower respiratory tract infections, B.3.11 Epidemic viral infection, B.17.1 Upper airway disease, B.17.2 Asthma.

**Type of course:** Lecture-based.

**Target audience:** Pulmonologists, emergency medicine doctors, respiratory physicians, clinical researchers, general practitioners, research fellows, intensivists, paediatricians, fellows in paediatric respiratory medicine.

**Chairs:** G. Rohde (Maastricht, The Netherlands), E. Eber (Graz, Austria)

- 14:00 Role of respiratory viral infections in the development of atopic conditions  
S. L. Johnston (London, United Kingdom)
- 14:45 Respiratory syncytial virus: a common threat  
J. Schwarze (Edinburgh, United Kingdom)
- 15:30 Break
- 16:00 Emerging respiratory viruses  
N. Regamey (Bern, Switzerland)
- 16:45 Bacteriological variety in chronic airway diseases  
S. Elborn (Belfast, United Kingdom)

**PG18 Postgraduate Course: Early detection of COPD: benefits and problems**

**Aims:** Under-diagnosis of COPD is a known problem, as only one out of three or four individuals with COPD have been diagnosed by the healthcare system in Europe. The course may contribute to detection of previously undiagnosed subjects with COPD. This is in many ways beneficial, as it increases the possibility of early intervention in smokers with mild COPD. There are, however, also problems both for the individuals who have so far regarded themselves as healthy, but are now labelled as having a disease, and for the healthcare system, which will have to handle a fairly large number of new patients after a screening event. The purpose of this Postgraduate Course is to discuss the benefits and problems with spirometric screening using experiences from both screening events and population studies.



**HERMES syllabus links:** B.1.4 COPD, B.1.3 Chronic bronchitis, B.6.1 Occupational asthma.

**Type of course:** Case- and problem-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, clinical researchers, general practitioners, nurses, research fellows.

**Chairs:** J. Garcia Aymerich (Barcelona, Spain), B. Stallberg (Uppsala, Sweden)

- 14:00 The impact of undiagnosed COPD in society  
J. Soriano (Bunyola, Spain)
- 14:45 How to manage COPD cases identified by population studies  
C. Janson (Uppsala, Sweden)
- 15:30 Break
- 16:00 COPD management in primary care: what are the challenges?  
D. Price (Aberdeen, United Kingdom)



- 16:45 Smoking characteristics and smoking behaviour in newly diagnosed COPD patients  
C. Pisinger (Glostrup, Denmark)

14:00 - 17:30

### PG19 Postgraduate Course: How to set up and deliver a smoking cessation service in a pulmonology department

**Aims:** To analyse the burden of smoking in COPD patients, to study the smoking characteristics of smokers with COPD, to show the psychological approach for smoking cessation in smokers with COPD, to show pharmacological treatments for smoking cessation in smokers with COPD, and to face smoking cessation of COPD smokers in a clinical setting.



**HERMES syllabus links:** B.1.4 COPD, B.6.8 Smoking-related disease, E.1.19 Smoking cessation.

**Type of course:** Lecture- and case-based.

**Target audience:** Pulmonologists, respiratory therapists, respiratory physicians, nurses, trainees, allied health professionals.

**Chairs:** A. Trofor (Iasi, Romania), C. Jimenez Ruiz (Madrid, Spain)

- 14:00 Epidemiological studies on COPD smokers  
D. Mannino (Lexington, United States of America)
- 14:45 Smoking characteristics of COPD smokers  
S. Nardini (Vittorio Veneto, Italy)
- 15:30 Break
- 16:00 Psychological approach to smoking cessation in COPD smokers  
C. Gratzou (Athens, Greece)
- 16:45 Pharmacological treatment for smoking cessation on COPD smokers  
K. Fagerstrom (Kågeröd, Sweden)

14:00 - 17:30

### PG20 Postgraduate Course: Biomarkers in respiratory medicine

**Aims:** To illustrate the progress in developing new biomarkers and how to use them in clinical practice.



**HERMES syllabus links:** B.1.1 Asthma, B.1.4 COPD, B.3.2 Lower respiratory tract infections, B.7 Diffuse parenchymal (interstitial) lung diseases, B.2.1 Lung cancer.

**Type of course:** Lecture-based.

**Target audience:** Pulmonologists, respiratory physicians, clinical researchers, general practitioners, research fellows, allergologists.

**Chairs:** M. Cazzola (Rome, Italy), J. Vansteenkiste (Leuven, Belgium)

- 14:00 Biomarkers in asthma and COPD  
R. Djukanovic (Southampton, United Kingdom)
- 14:45 Biomarkers in lower respiratory tract infections  
D. Stolz (Basel, Switzerland)
- 15:30 Break
- 16:00 Biomarkers in pulmonary fibrosis  
U. Costabel (Essen, Germany)
- 16:45 Biomarkers for lung cancer screening  
G. Scagliotti (Orbassano, Italy)

## Primary Care day

### This one-day programme offers:

- an excellent networking opportunity between respiratory care specialists, allied health professionals and GPs
- a state of the art on primary care clinical problems, scientific insights, teamwork and innovations in primary care
- a prime venue to share new developments in respiratory primary care, and learn from peers all over the world

### Target audience:

- respiratory specialists
- GPs
- nurses
- allied health professionals
- patient group representatives

Online registration will open in April.

*"Dear Colleagues,*

*A warm welcome to the Primary Care Day on September 24th 2011 at the Amsterdam ERS Congress! It is the pleasure of all officers involved in respiratory General Practice, Primary Care and Allied Health at ERS to invite you to the Third Primary Care Day. Earlier editions in Glasgow and Stockholm were characterised by lively discussions across boundaries, and a broad program covering respiratory issues from daily work to the latest scientific insights.*

*With kind regards,*

*Niels H. Chavannes, MD, PhD"*

### Primary Care day

09:30 - 13:00

#### I "Effective disease- and self-management in primary care"

- 09:30 Applicability of pulmonary rehabilitation in primary care - critical success factors, use of patient reported outcomes and consequences of population differences
- 10:00 Integrated disease management of COPD: role of self-management and internet support
- 10:30 Models of delivering COPD care: workforce, networks and training
- 11:00 Coffee break
- 11:30 Relevance of the primary care paradox for respiratory health: evidence of benefit for people and populations with asthma and COPD
- 12:00 Successful multidisciplinary smoking cessation treatment in primary care: novel options for both nurse and general practitioner
- 12:30 Improving patient and care outcomes by multidisciplinary integrated care for obstructive lung disease

### Primary Care day

14:00 - 17:30

#### II "Quality of assessment and diagnosis"

- 14:00 Lower limits of normal: to support COPD diagnosis and management with the individual in the centre
- 14:30 Quality of diagnostic and therapeutic services: how do we deliver and assess/monitor them?
- 15:00 Standards of training and delivery of spirometry and blood gases in primary care
- 15:30 Coffee break
- 16:00 Oxygen assessment: how, when, what? (long-term oxygen therapy, ambulatory, nocturnal and short burst)
- 16:30 Pulmonary rehabilitation: how to maintain quality over quantity in haste
- 17:00 Accreditation of respiratory services in primary care

# | SCIENTIFIC PROGRAMME

## |SCIENTIFIC PROGRAMME

This information is valid up to 13 May 2011.  
Visit [www.erscongress2011.org](http://www.erscongress2011.org) for updates.

## CEREMONY

8:30 - 08:55

**ERS Paediatric Research Awards Ceremony (supported by Merck)**

## followed by

8:55 - 10:30

**"Paediatric Grand Round - an interactive session"**

**Aims:** The audience will acquire a clinical update of genetics, presentations, assessment and care of children with challenging lung diseases.

**Target Audience:** Paediatric cases will be presented. These cases represent lung diseases specific for children but also representing respiratory problems in general. The session could be of interest for any clinician.

- 08:55 What was the cause of respiratory failure in this new-born infant?  
 09:20 2.5 year old boy with pleural empyema and lung abnormalities  
 09:45 A child with recurring episodes of cyanosis and cough  
 10:05 Falling off the hoarse

8:30 - 10:30

**Symposium: Live and let dive: diving and lung health**

**Aims:** The aims of this symposium are to:

- explain what the long-term effects are on the lungs in divers and especially on divers with large lungs;
- explain and display new tests, like NO diffusing capacity, as a necessity to include in the physical examination of the professional diver;
- give insight in the respiratory system while diving, with or without apparatus, with or without enriched mixtures.

**Target audience:** Clinicians, healthcare scientists and technologists in physiology, primary care doctors, lung function technologists and all involved in physiological diagnostics.

**Chairs:** B. G. Cooper (Birmingham, United Kingdom), R. Van Hultst (Den Helder, The Netherlands)

- 08:30 What we need to tell the patient with lung disease wanting to dive  
 I. Sibley-Calder (Hornsea, United Kingdom)  
 09:00 Lung volume and diving performance in breath-holding deep divers  
 E. Schagatay (Ostersund, Sweden)  
 09:30 Pulmonary oxygen toxicity in divers  
 P. Van Ooij (Den Helder, The Netherlands)  
 10:00 Diving with large lungs: is the diver at risk or not?  
 S. Watt (Aberdeen, United Kingdom)

8:30 - 10:30

**Symposium: Small airways: important in COPD and severe asthma**

**Aims:** The objective of this session will be to increase knowledge and awareness on the topic of small airways in asthma and in COPD.

Therefore, the session could include an overview of the role of small airways in the pathophysiology of asthma and COPD in general and in specific phenotypes. Next, a lecture focused on the need of parameters different from the forced expiratory volume in 1 to assess small airways impairment would be appropriate. Finally, a review of the studies demonstrating the added benefit of treatments able to reach also the distal lung in the management of asthma and COPD patients would close the session.

**Target audience:** Clinicians, clinical researchers, pharmaceutical companies.

**Chairs:** P. J. Barnes (London, United Kingdom), P. J. Sterk (Amsterdam, The Netherlands)

- 08:30 The role of small airways in asthma pathophysiology  
 Q. Hamid (Montreal, Canada)  
 09:00 The role of small airways in COPD pathophysiology  
 J. Hogg (Vancouver, Canada)  
 09:30 Assessing small airways impairment: techniques and parameters  
 O. Usmani (London, United Kingdom)  
 10:00 Clinical relevance and implication for therapy  
 D. S. Postma (Groningen, The Netherlands)

**Symposium: Prognostic and predictive factors in lung cancer**

**Aims:** The audience will improve its knowledge about the role of these prognostic and predictive factors, how they can predict survival, how to identify patients who will benefit from some specific treatment and how to validate such markers in clinical practice.

**Target audience:** Physicians (chest physicians, thoracic surgeons, radiation oncologists and medical oncologists) and nurses involved in lung cancer treatment.

**Chairs:** A.-P. Meert (Brussels, Belgium), N. Schoenfeld (Berlin, Germany)

- 08:30 Independent prognostic factors and prognostic classifications: how can we predict survival on the basis of clinical, pathological and routine biological factors?  
E. Quoix (Strasbourg, France)
- 09:00 What additional value for molecular biological factors and for gene profiling?  
Speaker to be confirmed
- 09:30 Predictive factors: can we identify patients who will benefit from a specific treatment?  
M. Tsao (Toronto, Canada)
- 10:00 How can we validate a predictive factor and bring it into clinical practice?  
M. Paesmans (Brussels, Belgium)

**Symposium: The burden of pulmonary hypertension in respiratory disease**

**Aims:** The aims of this symposium are:

- to give an overview of the characteristic histology and cellular aspects of pulmonary hypertension secondary to respiratory diseases, with an emphasis on the role of hypoxia;
- to provide the audience with an overview of the incidence, prevalence and prognostic significance of pulmonary hypertension in several respiratory diseases;
- to obtain insight into the effects of respiratory disease on the pre-load, after-load and interventricular dependency of the right ventricle;
- to provide an overview of current pre-clinical research in the field of pulmonary hypertension secondary to lung disease.

**Target audience:** Pulmonologists, cardiologists, residents, clinical research fellows, researchers in the field of the pulmonary circulation, nurses, and pathologists.

**Chairs:** A. Peacock (Glasgow, United Kingdom), J. Barbera Mir (Barcelona, Spain)

- 08:30 Pulmonary vascular remodelling in pulmonary disease  
P. Dorfmüller (Le Plessis-Robinson, France)
- 09:00 Pulmonary hypertension in various types of respiratory diseases  
V. Cottin (Lyon, France)
- 09:30 The consequence of pulmonary hypertension on the right ventricle: physiological concepts  
A. Vonk Noordegraaf (Amsterdam, The Netherlands)
- 10:00 Future research directions of pulmonary hypertension secondary to lung disease  
R. Schermuly (Bad Nauheim, Germany)

**Hot Topic: Fixed ratio or other ways to define COPD: what can we learn from others?**

**Aims:** The aims of this session are to:

- review how we define (and how we should define) obstructive respiratory diseases
- learn from the history lessons from other disciplines also dealing with diseases associated with aging and tobacco, with close to arbitrary definitions within a continuum, and with incomplete knowledge of their natural history and associated risks (hypertension, diabetes, etc.), yet with success stories in prevention, diagnosis, control and treatment.

**Target audience:** Public health practitioners and policy makers, physiologists, clinicians, primary care, technicians and allied respiratory fields, statisticians and other methodologists, and epidemiologists.

- 08:30 Current issues and gaps to extrapolate COPD population data on current global burden of diseases and future trends
- 09:00 Why and how we defined hypertension with the 140/90: a success story
- 09:30 Conspiracy theory in tobacco-related respiratory diseases
- 10:00 Making sense of COPD definitions and data to the general practitioner, the pulmonologist and the epidemiologist

**Sadoul Lecture: Sadoul Lecture followed by a session of Assembly 9 "How to get the best signal?"**

- 10:45 Spirometry: from health to disease  
M. Miller (Birmingham, United Kingdom) – 2011 Sadoul Lecturer
- 11:30 Exercise testing: getting the best signal
- 11:55 Gas transport: getting the best signal in critical care
- 12:20 Lung mechanics: getting the best signal

### Symposium: Idiopathic pulmonary fibrosis: translational insights and therapeutical approaches

**Aims:** The aims of this symposium are to:

- summarise the results of clinical trials of novel approaches to treatment and how it could change current management of idiopathic pulmonary fibrosis (IPF) patients;
- learn about translational research in lung fibrosis and better understanding the main mechanisms of action implicated in the pathogenesis of IPF.

**Target audience:** Pulmonary physician scientists and scientists involved in or interested in basic science or translational research in IPF, clinicians treating patients with lung fibrosis who desire to better understand the biology of the disease and pulmonary fellows interested in developing clinical or research career involving lung fibrosis.

**Chairs:** T. Geiser (Bern, Switzerland), V. Cottin (Lyon, France)

- 10:45 What we know from current and past clinical trials  
R. Du Bois (Denver, United States of America)
- 11:15 Extracellular matrix metabolism and matrix metalloproteases: what to treat?  
G. Laurent (London, United Kingdom)
- 11:45 The complex role of growth factors: how to regulate this pro-fibrotic switch?  
B. Crestani (Paris, France)
- 12:15 Cellular plasticity and tissue remodelling in lung fibrosis  
O. Eickelberg (Munich, Germany)

### Symposium: Macrophage heterogeneity in respiratory diseases

**Aims:** The audience will learn about novel findings in the field of immunology and how these apply to respiratory diseases. They will learn what we already know about the role of macrophages in respiratory diseases, where our challenges lie and the exciting new possibilities for the development of new drugs.

**Target audience:** Researchers in respiratory science, clinicians and the pharmaceutical industry.

**Chairs:** P. Hiemstra (Leiden, The Netherlands), Van Ginderachter, J (, Belgium)

- 10:45 Macrophage activation and polarisation  
F. Martinez Estrada (Oxford, United Kingdom)
- 11:15 Macrophage heterogeneity in the pathogenesis of COPD  
L. Donnelly (London, United Kingdom)
- 11:45 Alternatively activated macrophages as cause or effect in asthma  
B. Melgert (Groningen, The Netherlands)
- 12:15 Foamy macrophages and the progression of tuberculosis  
F. Altare (Nantes, France)

### Symposium: Mechanical ventilation: the American versus the European approach

**Aims:** The aims of this session are to compare:

- Europeans and American approaches to noninvasive ventilation;
- Europeans and American approaches to weaning from mechanical ventilation.

**Target audience:** Physicians, allied respiratory professionals, and anyone involved with mechanical ventilation.

**Chairs:** S. Nava (Bologna, Italy), S. Giordano (Irving, United States of America)

- 10:45 Noninvasive ventilation in the United States of America  
D. Hess (Boston, United States of America)
- 11:15 Noninvasive ventilation in Europe  
M. Chatwin (London, United Kingdom)
- 11:45 Weaning from mechanical ventilation in the USA  
T. Myers (Cleveland, United States of America)
- 12:15 Weaning from mechanical ventilation in Europe  
P. Navalesi (Vercelli, Italy)

### Symposium: Novelties in lung transplantation

**Aims:** The aim is to give a broad overview of novelties in the field of lung transplantation.

**Target audience:** Clinicians, surgeons, anesthetists.

**Chairs:** F. Meloni (Pavia, Italy), A. Boehler (Zurich, Switzerland)

- 10:45 Ex-vivo reconditioning of potential donor lungs  
A. Fisher (Newcastle, United Kingdom)



- 11:15 Bronchiolitis obliterans syndrome: still a valid terminology to reflect chronic rejection?  
M. Iversen (Copenhagen, Denmark)
- 11:45 Recent insights into chronic lung allograft dysfunction using genomics, proteomics, and animal models  
M. Hertz (Minneapolis, United States of America)
- 12:15 Treatment of bronchiolitis obliterans syndrome: where are we now?  
G. Verleden (Leuven, Belgium)

10:45 - 12:45

### Symposium: New advances in smoking cessation

**Aims:** The aims of the symposium are to:

- review and update the specific psychological and pharmacological approaches for smoking cessation;
- provide expert opinion on how to implement simple and effective smoking cessation programmes in the clinical setting of a respiratory diseases department;
- allow participants to earn more advanced knowledge on smoking cessation approaches in difficult categories of smokers such as hard-core smokers with smoking-related pulmonary disorders.

**Target audience:** Pulmonologists, physiologists and allied respiratory professionals.

**Chairs:** A. Trofor (Iasi, Romania), C. Jimenez Ruiz (Madrid, Spain)

- 10:45 What kind of psychological support can physicians provide?  
P. Hajek (London, United Kingdom)
- 11:15 What kind of pharmacological combination therapies are useful for smoking cessation?  
P. Tonnesen (Gentofte, Denmark)
- 11:45 How to optimise the efficacy of pharmacological treatments?  
K. Fagerstrom (Kågeröd, Sweden)
- 12:15 How do you manage hard-core smokers with smoking-related pulmonary disorders?  
Y. Martinet (Vandoeuvre-Les-Nancy, France)

### MEET THE PROFESSOR SEMINARS

13:00 - 14:00

- **Meet the Professor: Rehabilitation as part of lung cancer management?**  
M. A. Spruit (Horn, The Netherlands)
- **Meet the Professor: Lung ultrasound in critically ill patients**  
J. Rouby (Paris, France)
- **Meet the Professor: Mild COPD: what's all the fuss?**  
D. Marciniuk (Saskatoon, Canada)
- **Meet the Professor: How to select OSA patients for upper airway interventions**  
W. De Backer (Antwerp, Belgium)
- **Meet the Professor: Management of severe asthma**  
G. Brusselle (Ghent, Belgium)
- **Meet the Professor: Primary ciliary dyskinesia: current state of the art**  
C. O Callaghan (Leicester, United Kingdom)

14:45 - 16:45

### Grand Round: Interventional Pneumology Grand Round - an interactive session

**Aims:** Based on the presented cases, the medical decisions will be discussed and compared with the available evidence.

**Target audience:** Clinicians, pulmonologists, surgeons, residents and fellows.

**Chairs:** V. Schluessens (Arhus, Denmark), B. Nemery (Leuven, Belgium)

- 14:45 An 85 years old man with complete collapse of the left lung
- 15:15 53 year old patient with a leaky lung story
- 15:45 83 year old patient with shortness of breath when dancing competitively
- 16:15 A 60 year old male with acute shortness of breath

**Symposium: New promising ways to treat cystic fibrosis**

**Aims:** The aim of this symposium is to increase the knowledge of the basic defect in cystic fibrosis (CF) and the clinical consequences. To inform about the therapies well under way that may circumvent the basic defect and hopefully improve outcome without increasing the use of broad-spectrum antibiotics.

**Target audience:** Clinicians, paediatric and adult pulmonologists, researchers, physiotherapists and nurses.

**Chairs:** D. Bilton (London, United Kingdom), H. Tiddens (Rotterdam, The Netherlands)

- 14:45 New targets for CF therapies: hyperosmolar agents  
I. Sermet-Gaudelus (Paris, France)
- 15:15 Correctors and potentiators - to treat patients with individual mutations  
E. Kerem (Jerusalem, Israel)
- 15:45 Denufosal, a P2Y2 agonist that activates alternative chloride channels  
F. Ratjen (Toronto, Canada)
- 16:15 Neutrophil elastase inhibitor in CF: can it be done and will it help?  
S. Elborn (Belfast, United Kingdom)

**Symposium: Acute breathlessness: the state of the science**

**Aims:** At the end of the session, participants will be able to define and describe dyspnoea crisis, identify key aspects related to dyspnoea crisis, and discuss the current evidence and gaps in the State of the Science. Participants will have the opportunity to engage in discussion with panellists on protocols that may be applied to their practices.

**Target audience:** Nurses working in hospice, emergency departments, intensive care units, palliative care, allied health care professionals, physician scientists, physician clinicians, palliative care specialists and primary care physicians.

**Chairs:** C. Hernandez (Barcelona, Spain), G. Burge (Birmingham, United Kingdom)

- 14:45 State of the science on communication and coordination of care for dyspnoea crisis  
L. Reinke (Seattle, United States of America)
- 15:15 Dyspnoea causal mechanisms and treatment options  
R. Jones (Plymouth, United Kingdom)
- 15:45 Novel approaches to delivery of services for patients experiencing dyspnoea crisis and their caregivers  
Speaker to be confirmed
- 16:15 Evidence base summary on the state of the science for dyspnoea crisis  
V. Carrieri-Kohlman (San Francisco, United States of America)

**Symposium: TBNET: tuberculosis research in Europe**

**Aims:** At the end of the symposium, attendees will be familiar with recent advances in tuberculosis research in Europe.

**Target audience:** Clinicians, clinical scientists, immunologists, microbiologists, specialist nurses and public health specialists involved in tuberculosis control, surveillance, care and research.

**Chairs:** D. Goletti (Rome, Italy), G. Bothamley (London, United Kingdom)

- 14:45 The role of interferon- $\gamma$  release assays for the diagnosis of tuberculosis  
C. Lange (Borstel, Germany)
- 15:15 Immunodiagnosis of latent tuberculosis infection in immunocompromised hosts  
M. Sester (Homburg, Germany)
- 15:45 Clinical management of patients with multidrug-resistant tuberculosis in Europe  
G. B. Migliori (Tradate, Italy)
- 16:15 The risk of tuberculosis related to tumour necrosis factor antagonist therapies  
I. Solovic (Vysne Hagy, Slovakia)

**Symposium: Knowing COPD by heart: a relationship beyond co-morbidity**

**Aims:** The aims of this symposium are to:

- raise awareness about a high prevalence of cardiovascular disease (CVD) in patients with COPD
- explain the underlying mechanisms for an increased cardiovascular risk in COPD
- discuss potential therapeutic implications of CVD in COPD.

**Target audience:** Chest physicians, physicians in training, researchers and cardiologists.

**Chairs:** O. C. Burghuber (Vienna, Austria), L. M. Fabbri (Modena, Italy)

- 14:45 Cardiovascular disease is a systemic manifestation of COPD: an introductory overview  
A. Valipour (Vienna, Austria)
- 15:15 Elastin loss and systemic vascular dysfunction in the lung and vasculature  
W. MacNee (Edinburgh, United Kingdom)

- 15:45 Sympathetic activation in COPD as a link to cardiovascular disease  
S. Andreas (Immenhausen, Germany)
- 16:15 The impact of cardiovascular drugs in COPD  
A. Anzueto (San Antonio, United States of America)

14:45 - 16:45

### Symposium: Accelerated lung aging in COPD

**Aims:** The aims of this symposium are to provide:

- an understanding of the normal aging process in lungs;
- the evidence for accelerated aging in emphysema/COPD;
- molecular mechanisms of aging;
- potential therapeutic targets for COPD therapy.

**Target audience:** Clinicians, researchers and the pharmaceutical industry.

**Chairs:** A. Agusti (Barcelona, Spain), Y. Fukuchi (Tokyo, Japan)

- 14:45 Modeling the aging lung function  
J. Soriano (Bunyola, Spain)
- 15:15 Telomere shortening and cell senescence in COPD  
S. Adnot (Creteil, France)
- 15:45 Molecular pathways of aging  
K. Ito (London, United Kingdom)
- 16:15 Therapeutic implications  
P. J. Barnes (London, United Kingdom)

### EVENING SYMPOSIUM

17:15 - 19:15

- **COPD - On Target**  
*Organised by Nycomed GmbH*
- **A holistic approach to improve understanding and management of COPD**  
*Organised by Boehringer Ingelheim/Pfizer*
- **Developing and delivering effective medicines by design**  
*Organised by GlaxoSmithKline*
- **Omalizumab and allergic asthma: latest clinical evidence and long-term safety data**  
*Organised by Novartis Pharma AG*
- **New decade, new approaches to respiratory tract infections**  
*Organised by Bayer Schering Pharma*
- **The poorly explored impacts of uncontrolled asthma**  
*Organised by AstraZeneca*
- **Combination therapy in asthma: What influences real-world effectiveness?**  
*Organised by Mundipharma*
- **Pneumococcal Disease in Adults: a remaining challenge...**  
*Organised by Pfizer Ltd*
- **Pulmonary Arterial Hypertension: Optimising Management for Today – Developing New Therapies for Tomorrow**  
*Organised by Actelion Pharmaceuticals Ltd*
- **IPF-new knowledge, new hopes for patients**  
*Organised by InterMune, Inc.*
- **The 2011 PAH Debate: What is the Biggest Challenge We Face to Optimise Patient Outcome?**  
*Organised by United Therapeutics Europe, Ltd.*

07:00 - 08:15

**Morning Seminar: Extending bronchial challenge testing in the lab****Chairs:** V. Moore (Birmingham, United Kingdom)

- 07:00 Introduction from the chair  
V. Moore (Birmingham, United Kingdom)
- 07:10 The role of challenge testing in aspirin hypersensitivity  
A. Szczeklik (Cracow, Poland)
- 07:35 Bronchial challenge testing in athletes: exercise, eucapnic hyperventilation or mannitol?  
B. Dahlen (Stockholm, Sweden)
- 08:00 Discussion

07:00 - 08:15

**Morning Seminar: Interpretation of sleep studies: problem areas****Chairs:** S. Andreas (Immenhausen, Germany)

- 07:00 Introduction from the chair  
S. Andreas (Immenhausen, Germany)
- 07:10 Diagnostic sleep studies in sleep apnoea with comorbidity  
J. Verbraecken (Antwerp, Belgium)
- 07:35 Monitoring of treatment success  
K. E. Bloch (Zurich, Switzerland)
- 08:00 Discussion

**CEREMONY**

08:30 - 08:55

**ERS Award for Rare Pulmonary Disease Ceremony (supported by GlaxoSmithKline)****followed by**

08:55 - 10:30

**“Clinical Grand Round - an interactive session”**

**Aims:** This grand round will discuss important topics in general pulmonology practice by showing four interesting cases with distinct problems of diagnosis and treatment. The case presentation given by experts will follow an interactive format and include an update of the most recent literature.

**Target audience:** Clinicians and trainees interested in clinical practice and in the clinical reasoning process in an up-to-date methodology.

- 08:55 A 65 year old woman with lung mass and pleural effusion
- 09:20 Doctor, this breathlessness is a pain in the neck
- 09:45 Reversible dyspnea in Alpha-1 antitrypsin deficiency
- 10:05 A Doctor House Syndrome or a tricky diagnosis of interstitial lung disease

08:30 - 10:30

**Symposium: The non-pharmacological management of COPD exacerbations**

**Aims:** The aims of this symposium are to:

- understand the non-pharmacological management of COPD exacerbations across lines of healthcare;
- increase the attention for the non-respiratory consequences and their treatment (muscle dysfunction and comorbidity).

**Target audience:** Clinicians in all lines of healthcare, physiotherapists, nurses and legislators.

**Chairs:** T. Troosters (Leuven, Belgium), M. A. Spruit (Horn, The Netherlands)

- 08:30 Assessment of exacerbations: moving the field forward using patient reported outcome tools  
N. Leidy Klein (Bethesda, United States of America)
- 09:00 Chest physiotherapy during exacerbations: is there an added value?  
J. Cross (Norwich, United Kingdom)
- 09:30 Rehabilitation: the sooner the better?  
J. Seymour (London, United Kingdom)
- 10:00 Assessment and treatment of comorbidity: what efforts pay off?  
W. Janssens (Leuven, Belgium)

08:30 - 10:30

### Symposium: ERS/ESCMID Guidelines “Management of Lower Respiratory Tract Infections: Scores, Biomarkers and Beyond”

**Aims:** During this session, the “ERS/ESCMID Guidelines for the Management of Adult Lower Respiratory Tract Infections III” will be presented. The audience will learn about how to choose and use clinical scoring systems, which biomarkers help to better define choice of treatment and prognosis, and what current guidelines put forward and what future guidelines will recommend for the management of lower respiratory tract infections.

**Target audience:** Clinicians, specialists and general practitioners.

**Chairs:** G. Rohde (Maastricht, The Netherlands), M. Miravittles (Barcelona, Spain)

- 08:30 Clinical scoring systems for lower respiratory tract infections  
R. Menendez (Valencia, Spain)
- 09:00 Aetiological and prognostic biomarkers in lower respiratory tract infections  
B. Muller (Basel, Switzerland)
- 09:30 The current ERS guidelines for management of lower respiratory tract infections  
M. Woodhead (Manchester, United Kingdom)
- 10:00 Looking forward the next European lower respiratory tract infections guidelines  
S. Ewig (Bochum, Germany)

08:30 - 10:30

### Symposium: Diagnosis and management of mediastinal tumours

**Aims:** Participants will be offered an overview on the diagnostic work-up and the management of these tumours.

**Target audience:** Pulmonary clinicians, including trainees, thoracic surgeons and oncologists.

**Chairs:** B. Grigoriu (Iasi, Romania), A.-P. Meert (Brussels, Belgium)

- 08:30 Rare mediastinal tumours: a spectrum of the disease and potential future directions  
N. Girard (Bron, France)
- 09:00 Thoracic imaging for the assessment of mediastinal masses  
T. Franquet (Barcelona, Spain)
- 09:30 Endoscopic ultrasound of diagnosis of mediastinal tumours  
R. Eberhardt (Heidelberg, Germany)
- 10:00 Management of Superior Vena Cava Syndrome: current status  
R. Uberoi (Oxford, United Kingdom)

08:30 - 10:30

### Symposium: End-stage lung disease in children

**Aims:** Primarily clinical – to give attendees a state-of-the-art update on investigation and management of these difficult clinical scenarios.

**Target audience:** Paediatricians, cystic fibrosis physicians, intensivists and neonatologists, transplant physicians and surgeons, paediatric psychologists and nurses.

**Chairs:** A. Fisher (Newcastle, United Kingdom), R. Ross-Russell (Cambridge, United Kingdom)

- 08:30 End-stage cystic fibrosis: what to measure and what to try?  
F. Ratjen (Toronto, Canada)
- 09:00 Options for technological support  
B. Fauroux (Paris, France)
- 09:30 Lung transplantation in children  
P. Aurora (London, United Kingdom)
- 10:00 When everything fails: how should the end of life be managed?  
W. Robinson (Nashville, United States of America)

08:30 - 10:30

### Symposium: The unfolding story of endoplasmic reticulum stress signalling in lung disease

**Aims:** The aims of this session are to provide a set of comprehensive, thought-provoking and interesting presentations on the topic of endoplasmic reticulum (ER) stress. Attendees will be given a broad introduction to the topic by an internationally renowned expert in the area describing the causes, mechanisms and outcomes of ER stress. This will be followed by presentations describing new advances in our understanding of ER stress responses and how they can contribute to the pathogenesis of COPD and cystic fibrosis. Finally there will be a presentation on the targeting of ER stress for lung cancer treatment.

**Target audience:** The target audience for this symposium includes basic scientists, clinician scientists and clinicians with specific interests in COPD, cystic fibrosis and lung cancer therapeutics.

The content will be of interest to members of Assemblies 1, 3, 5 and 11 and Group 7.3.

**Chairs:** P. Hiemstra (Leiden, The Netherlands), C. Greene (Dublin, Ireland)

- 08:30 The unfolded protein response in lung disease  
S. Marciniak (Cambridge, United Kingdom)
- 09:00 Endoplasmic reticulum stress in COPD: implications for alpha1-antitrypsin deficiency  
T. P. Carroll (Dublin, Ireland)
- 09:30 Endoplasmic reticulum stress and inflammatory responses relevant to cystic fibrosis airways  
C. Ribeiro (Chapel Hill, United States of America)
- 10:00 Targeting the endoplasmic reticulum stress response as an anticancer strategy  
A. Samali (Galway, Ireland)

## CEREMONY

10:45 - 11:05

**Maurizio Vignola Award on Innovation in Pneumology Ceremony**  
(supported by Chiesi Foundation)

## followed by

11:05 - 12:45

### “Science Year in Review”

**Aims:** An update on important scientific developments that are of future clinical relevance.

**Target audience:** Clinicians, scientists, researchers and pharmaceutical companies.

- 11:05 Inflammasomes in inflammatory lung disease
- 11:30 Th17 cells in inflammatory lung diseases
- 11:55 Towards an artificial lung
- 12:20 TIM genes in allergic inflammation

10:45 - 12:45

## Symposium: The prognostic value of cardiopulmonary exercise testing

**Aims:** The audience will be introduced to and updated on the evidence supporting the use of cardiopulmonary exercise testing as a prognostic tool.

**Target audience:** Physiologists, researchers and clinicians interested in the use of cardiopulmonary exercise testing in clinical practice and research.

**Chairs:** L. Puente Maestú (Madrid, Spain), P. Palange (Rome, Italy)

- 10:45 The survival of the fittest: maximal oxygen uptake and survival overview  
J. Myers (Palo Alto, United States of America)
- 11:15 The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis  
K. Flaherty (Ann Arbor, United States of America)
- 11:45 Prediction of mortality: what variables should we consider?  
M. Puhon (Zurich, Switzerland)
- 12:15 Importance of cardiopulmonary exercise testing in the assessment of patients with primary pulmonary hypertension  
R. Naeije (Brussels, Belgium)

10:45 - 12:45

## Symposium: The digital highway: innovative monitoring of asthma

**Aims:** The audience will get an overview on new, practical tools to assess and improve asthma control of their patients by using innovative ways of monitoring and using the newest home-monitoring tools.

**Target audience:** Paediatricians, paediatric pulmonologists, fellows, nurses, respiratory physicians and allied respiratory professionals.

**Chairs:** Chairs to be confirmed

- 10:45 Monitoring asthma in childhood: what tools are available and documented?  
M. Pijnenburg (Rotterdam, The Netherlands)
- 11:15 Internet-based home-monitoring of adolescents with asthma  
J. Sont (Leiden, The Netherlands)
- 11:45 Telemonitoring of symptoms, lung function and exhaled nitric oxide  
S. Carraro (Padova, Italy)
- 12:15 Improving adherence to asthma treatment: motivational interviewing  
K. Riekert (Baltimore, United States of America)



**Hot Topic: The value of patients as partners in research**

**Aims:** The audience of this session will have the opportunity to hear, discuss and gain information on:

- the benefits that can be gained from having patients as active partners in research
- the challenges that might be faced when involving patients in research and how these can be overcome
- examples of different levels of patient involvement in research and the outcomes
- methods that can be employed to better engage the patient
- insights into the level of information that should be provided to patients and training required
- mechanisms for increasing patient participation

**Target audience:** Clinical researchers and epidemiologists, pharmaceutical, basic science and genomics specialists who are involved in research and seeking ways to involve patients meaningfully in their research. The symposium will also target patients and patient organisations attending the congress as part of the ELF strategy to engage these groups in the life and work of the ERS. Industry will benefit from the debate.

- 10:45 Patients as partners in research: the goal
- 11:15 Active patient participation in research and research policy making
- 11:45 The added value of active patient participation in care and research
- 12:15 Workable instruments and tools realising active patient participation: a set of criteria from the patient's perspective

**Symposium: Epidemiology of COPD exacerbations**

**Aims:** This session will provide an update on the knowledge of various aspects of the epidemiology of COPD exacerbations, such as prevalence, incidence, risk factors and health economy.

**Target audience:** Clinicians, general practitioners and nurses.

**Chairs:** B. Lundback (Gothenburg, Sweden), R. Rodríguez-Roisin (Barcelona, Spain)

- 10:45 The prevalence, the incidence and the cost of COPD exacerbations  
C. Janson (Uppsala, Sweden)
- 11:15 The role of infections as a trigger of COPD exacerbations and decline of lung function  
J. Wedzicha (London, United Kingdom)
- 11:45 Biomarkers in COPD exacerbations  
P. Bakke (Bergen, Norway)
- 12:15 Exacerbations of and prognosis in COPD: population and clinical approaches  
J. Soriano (Bunola, Spain)

**Symposium: Vasculitis and the lung**

**Aims:** This comprehensive symposium will present the latest information on the pathology, imaging, clinical features, and treatment of pulmonary vasculitides, with special emphasis on recent advances in the field.

**Target audience:** Clinicians and chest physicians.

**Chairs:** J-F. Cordier (Lyon, France), C. Robalo Cordeiro (Coimbra, Portugal), Y. Inoue (Osaka, Japan)

- 10:45 Imaging spectrum and diagnostic pitfalls of pulmonary vasculitides  
S. Desai (London, United Kingdom)
- 11:15 From asthma to systemic eosinophilic disease  
V. Cottin (Lyon, France)
- 11:45 From alveolar haemorrhage to pulmonary renal syndrome  
M. Schwarz (Aurora, Co, United States of America)
- 12:15 Update in the management of Wegener granulomatosis  
C. Pagnoux (Toronto, Canada)

**MEET THE PROFESSOR SEMINARS**

- **Meet the Professor: Is the increase in asthma prevalence over in Europe? And worldwide?**  
B. Lundback (Gothenburg, Sweden)
- **Meet the Professor: Post-transplant infections: diagnosis and treatment**  
C. Chaparro (Toronto, Canada)
- **Meet the Professor:  $\beta$ -blockers in respiratory medicine**  
N. Hanania (Houston, United States of America)

**MEET THE PROFESSOR SEMINARS****13:00 - 14:00**

- **Meet the Professor: Antibiotic treatment of exacerbations of COPD: when, why... and how?**  
S. Sethi (Buffalo, United States of America)
- **Meet the Professor: What is the optimal lymph node staging algorithm in locoregional nonsmall-cell lung cancer? PRO/CON DEBATE**  
G. Massard (Strasbourg, France), J. Annema (Leiden, The Netherlands)
- **Meet the Professor: Strategies for treating idiopathic pulmonary fibrosis**  
R.M. Du Bois (London, United Kingdom)

**CEREMONY****14:45 - 15:05****Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline)****followed by****15:05 - 16:45****"Imaging of the lung parenchyma - an interactive session on interpretation strategies"**

**Aims:** The aim of this session is to demonstrate and discuss characteristic imaging findings in patients with decrease and increase in lung density based on individual patients history, providing imaging strategies for different patient populations.

**Target audience:** Clinicians and all health professionals caring for patients with various lung diseases requiring imaging for non-invasive disease characterisation.

- 15:05 Patients with decreased lung attenuation
- 15:30 Airspace opacities
- 15:55 Patients with ground glass opacities
- 16:20 Patients with septal thickening

**14:45 - 16:45****Session: Paediatric Year in Review**

**Aims:** The audience will receive an overview and an update on the topics/diseases that will be presented by experienced clinicians.

**Target audience:** The subjects of the session covers a wide variety of topics relevant to paediatricians but also to other clinically active physicians and health professionals.

- 14:45 Bacterial infections and community-acquired pneumonia in children
- 15:15 Problematic severe asthma in children
- 15:45 Environmental exposures and respiratory outcomes in children
- 16:15 Interstitial lung diseases in children

**14:45 - 16:45****Symposium: Highlights in the treatment of pleural empyema**

**Aims:** Based on the published literature, the new details of treatment will be described and possible clinical algorithms will be presented and discussed.

**Target audience:** Clinicians, pulmonologists, surgeons, paediatricians, residents and fellows.

**Chairs:** E. Canalis (Barcelona, Spain), M. Confalonieri (Trieste, Italy)

- 14:45 New antibiotic and other medical options for treatment of non-tuberculous empyema according to its classification  
F. Blasi (Milan, Italy)
- 15:15 Evidence-based indications for pleurofibrinolysis  
F. Rodriguez Panadero (Seville, Spain)
- 15:45 Chronic empyema: should we operate?  
A. End (Vienna, Austria)
- 16:15 Special characteristics of empyema in children  
S. Sonnappa (London, United Kingdom)

**Symposium: Cancer tissue is the issue**

**Aims:** Based on the published literature, the new techniques will be described and possible clinical algorithms will be presented and discussed.

**Target audience:** Clinicians, pulmonologists, surgeons, oncologists, general practitioners, residents and fellows.

**Chairs:** J-P. Sculier (Brussels, Belgium), 2nd Chair to be confirmed

- 14:45 Biomarkers in lung cancer  
E. Brambilla (Grenoble, France)
- 15:15 What the tissue sampler can offer  
F. Herth (Heidelberg, Germany)
- 15:45 What the pathologist can do  
P. Schnabel (Heidelberg, Germany)
- 16:15 What the thoracic oncologist asks for  
R. M. Huber (Munich, Germany)

**Symposium: Innate immune responses in COPD and severe asthma: new targets for therapy?**

**Aims:** This session will provide:

- cutting-edge knowledge on innate immunity in highly prevalent and difficult-to-treat airway diseases;
- a current understanding for shared and distinct innate immune mechanisms in COPD and severe asthma;
- insights into potential new therapeutic strategies that emphasise molecular mechanisms for innate immune responses.

**Target audience:** Clinicians, scientists and research fellows.

**Chairs:** B. Levy (Boston, United States of America), G. Anderson (Parkville, Australia)

- 14:45 Targeting Toll-like receptors in lung disease: emerging therapeutics  
J. Mitchell (London, United Kingdom)
- 15:15 Annexin A1 signalling regulates neutrophil responses: a link to COPD pathogenesis  
F. D'Acquisto (London, United Kingdom)
- 15:45 Intraepithelial mast cells promote asthmatic airway responses  
J. Fahy (San Francisco, United States of America)
- 16:15 Dendritic cells in asthma and COPD: opportunities for drug development  
B. Lambrecht (Ghent, Belgium)

**Hot Topic: Bone marrow-derived stem cells in respiratory diseases: a future therapy?**

**Aims:** This session will update the audience on the current knowledge of the pathophysiologic and potential therapeutic role of bone marrow-derived mesenchymal stem cells and progenitor endothelial cells in relevant diseases, such as COPD, sleep apnoea, acute lung injury/acute respiratory distress syndrome and pulmonary hypertension.

**Target audience:** Clinicians and scientists.

- 14:45 Circulating progenitor cells in COPD patients
- 15:15 Bone marrow-derived mesenchymal stem cells in obstructive sleep apnoea
- 15:45 Bone marrow-derived mesenchymal stem cells in acute lung injury
- 16:15 Endothelial progenitors in pulmonary hypertension

**EVENING SYMPOSIUM**

- **Asthma and COPD management: real world experience put into practice**  
*Organised by AstraZeneca*
- **An integrated approach to COPD: Treating the patient, managing the disease**  
*Organised by Novartis Pharma AG*
- **Improving bronchodilation, symptoms and patient outcomes: aclidinium bromide, a new treatment option in COPD**  
*Organised by Almirall*
- **Anticholinergics in asthma: A new way forward?**  
*Organised by Boehringer Ingelheim/Pfizer (Spiriva Alliance)*
- **Asthma in 2011: New ways to improve your outcomes**  
*Organised by MSD*

## EVENING SYMPOSIUM

17:15 - 19:15

- **Bronchiectasis management: verging on a breakthrough? Join the debate!**  
*Organised by Bayer Schering Pharma*
- **Small airways – big impact**  
*Organised by Nycomed GmbH*
- **Idiopathic Pulmonary Fibrosis: Evolutions in diagnosis and treatment**  
*Organised by Boehringer Ingelheim GmbH*
- **Volibris Data in PAH: Clinical data to Registries**  
*Organised by GlaxoSmithKline*
- **Pulmonary Hypertension: new targets, new goals, new therapies?**  
*Organised by Bayer Schering Pharma*
- **AATD and COPD – Variation of a Theme**  
*Organised by Talecris Biotherapeutics GmbH*

07:00 - 08:15

**Morning Seminar: Assessing efficiency of mechanical ventilation: secrets of success****Chairs:** A. Simonds (London, United Kingdom)

- 07:00 Introduction from the Chair  
A. Simonds (London, United Kingdom)
- 07:10 How to make sure my acute patient is optimally ventilated  
S. Nava (Bologna, Italy)
- 07:35 How to assess the efficacy of long-term mechanical ventilation: what to measure and when?  
J-L. Pepin (Grenoble, France)
- 08:00 Discussion

07:00 - 08:15

**Morning Seminar: Interpreting high-resolution computed tomography scans: top tips****Chairs:** C. Vancheri (Catania, Italy), W. De Wever (Leuven, Belgium)

- 07:00 Introduction by the Chair
- 07:10 Bronchial and bronchiolar disorders  
Speaker to be confirmed
- 07:35 Interstitial lung diseases  
D. Hansell (London, United Kingdom)
- 08:00 Discussion

08:30 - 10:30

**Session: Clinical Year in Review I**

**Aims:** This session will offer the possibility to review four topics of paramount interest for clinicians and fellows in training. This will highlight the new and emerging clinical concepts in the management of respiratory related diseases and conditions.

**Target audience:** Clinicians, surgeons, allied health professionals involved in patient care and trainees.

- 08:30 Advances in rehabilitation and the acute exacerbation
- 09:00 Thoracic malignancies
- 09:30 Advances in interstitial lung diseases
- 10:00 Advances in lung transplantation

08:30 - 10:30

**Hot Topic: New dimensions in respiratory clinics - Peter Macklem memorial symposium**

**Aims:** After this session the audience will

- have a better understanding of what constitutes health and disease
- know the importance of fractiles and temporal dynamics in health and disease
- understand the different pathophysiological dimensions of asthma and COPD
- have knowledge of future developments in diagnosis, phenotyping and treatment of asthma and COPD.

This session is dedicated to the memory of Peter Macklem.

**Target audience:** Pulmonologists, paediatricians, basic scientists, physiologists, pathologists and geneticists.

- 08:30 The fundamentals of health and disease
- 09:00 Disease phenotyping using the swings of disease
- 09:30 Five dimensions of airway disease
- 10:00 Promises of modern physiology for the patient

08:30 - 10:30

**Symposium: Chronic bronchial infection: more than a syndrome**

**Aims:** The aims of this symposium are to:

- identify the characteristics of the syndrome of chronic bronchial infection (CBI);
- learn the risk factors for CBI and the microorganisms most frequently implicated;
- and get some insight into the new clinical trials of inhaled and oral antibiotics for treatment of CBI in bronchiectasis, cystic fibrosis (CF) and COPD.

**Target audience:** Clinicians, scientists, respiratory physiotherapists and microbiologists.

**Chairs:** T. Welte (Hannover, Germany), A. Anzueto (San Antonio, United States of America)

- 08:30 Concept and impact of the syndrome of chronic bronchial infection  
M. Miravittles (Barcelona, Spain)
- 09:00 Suppressive antimicrobial therapy in CBI: the example of cystic fibrosis  
D. Bilton (London, United Kingdom)

- 09:30 Strategies to control chronic bronchial infection in non-CF bronchiectasis  
E. Polverino (Barcelona, Spain)
- 10:00 Choosing the right antimicrobial, route of administration and dosage for chronic bronchial infection  
S. Sethi (Buffalo, United States of America)

08:30 - 10:30

### **Symposium: The times they are a-changing: how noninvasive ventilation changed our practice**

**Aims:** Noninvasive ventilation (NIV) has a broad spectrum of indications for treatment of acute patients. The session aims at describing well established and novel fields of application for noninvasive ventilation.

**Target audience:** Intensive care unit (ICU) physicians, pneumologists and respiratory physiotherapists.

**Chairs:** N. Hill (Providence, United States of America), A. Carlucci (San Donato Milanese, Italy)

- 08:30 NIV to prevent intensive care unit admission  
M. W. Elliott (Leeds, United Kingdom)
- 09:00 NIV to prevent intensive care unit infections  
A. Torres (Barcelona, Spain)
- 09:30 NIV to prevent post-operative complications  
S. Jaber (Montpellier, France)
- 10:00 NIV to prevent prolonged intubation  
P. Navalesi (Vercelli, Italy)

08:30 - 10:30

### **Symposium: Adenosine and purigenic signalling in inflammatory lung disease**

**Aims:** At the end of the session the audience will understand:

- that endogenously released ATP and adenosine are important regulators of the immune system;
- the complexity of P2 and adenosine receptor signalling in lung physiology;
- that specific P2R/adenosine receptor subtypes play a key role in the pathogenesis of inflammatory lung diseases;
- that ATP contributes to chronicity of inflammatory lung diseases and airway remodelling;
- that targeting specific P2R/adenosine receptors is a new therapeutic approach for the treatment of chronic inflammatory lung diseases, such as COPD, lung fibrosis and severe asthma.

**Target audience:** Clinicians, scientists, pharmacologists, pulmonary and research fellows and the pharmaceutical industry.

**Chairs:** J. C. Virchow (Rostock, Germany), C. Page (London, United Kingdom)

- 08:30 Introductory talk: Pharmacology of adenosine and purinergic signalling  
G. Folkerts (Utrecht, The Netherlands)
- 09:00 Adenosine signalling in asthma and COPD  
R. Polosa (Catania, Italy)
- 09:30 P2 receptor signalling in asthma and COPD  
M. Idzko (Freiburg, Germany)
- 10:00 Adenosine/P2R-signalling in lung fibrosis  
M. Blackburn (Houston, United States of America)

08:30 - 10:30

### **Symposium: Slow-growing lung cancer**

**Aims:** The audience will get a feeling for the problems associated with small nodules and screening, and discuss how to handle this common clinical problem.

**Target audience:** Clinicians, surgeons, biologists and pathologists.

**Chairs:** E. Quoix (Strasbourg, France), R. M. Huber (Munich, Germany)

- 08:30 Indolent lung cancers  
G. Hillerdal (Stockholm, Sweden)
- 09:00 Lung nodule: differential diagnosis  
R. Van Klaveren (Rotterdam, The Netherlands)
- 09:30 The role of FDG-PET-CTscan  
T. Berghmans (Brussels, Belgium)
- 10:00 To treat or not to treat: an important question  
M. Infante (Milan, Italy)



**CEREMONY****10:45 - 11:05****COPD Research Award Ceremony (supported by Boehringer Ingelheim)****followed by****11:05 - 12:45****“Clinical Year in Review II”**

**Aims:** This session will offer the possibility to review four topics of paramount interest for clinicians and fellows in training. This will highlight the new and emerging clinical concepts in the management of respiratory-related diseases and conditions.

**Target audience:** Clinicians, surgeons, allied health professionals involved in patient care and trainees.

- 11:05 Advances in sleep medicine
- 11:30 Advances in understanding the effects of outdoor pollution
- 11:55 Advances in COPD
- 12:20 Advances in acute critical care

**10:45 - 12:45****Symposium: New imaging tools for diagnosis of alterations in lung structure and function in COPD**

**Aims:** The aims of this session are to provide:

- an update on the most advanced imaging methods and techniques suitable for measuring regional lung function in COPD;
- an overview of the advantages and disadvantages of the different techniques;
- a general idea on which technique(s) is/are more suitable for different clinical applications.

**Target audience:** Physiologists, clinical investigators, respiratory physicians and thoracic surgeons.

**Chairs:** G. Miserocchi (Monza, Italy), R. Rodríguez-Roisin (Barcelona, Spain)

- 10:45 Tracheo-bronchial tree structure and function: assessment by computed tomography and computational fluid-dynamics  
W. De Backer (Antwerp, Belgium)
- 11:15 Alveolar structure in COPD: assessment by hyperpolarised helium and magnetic resonance imaging  
J. Woods (St-Louis, United States of America)
- 11:45 Airway wall structure in COPD: assessment by computed tomography and optical coherence tomography  
H. Coxson (Vancouver, Canada)
- 12:15 Regional specific gas volume and gas trapping in COPD by computed tomography  
A. Aliverti (Milan, Italy)

**10:45 - 12:45****Symposium: Respiratory complications after chest trauma: current management**

**Aims:** The aim of this symposium is to establish the basis for diagnosis and treatment of respiratory complications in trauma patients.

**Target audience:** Pulmonologists dealing with trauma patients, intensivists and thoracic surgeons.

**Chairs:** Chairs to be confirmed

- 10:45 Chest trauma  
G. Mattioli (Genoa, Italy)
- 11:15 Nowadays indications for surgical stabilisation of the chest wall  
J. Wihlm (Strasbourg, France)
- 11:45 Respiratory infections after chest trauma in the intensive care unit patient  
J. Rello Condomines (Barcelona, Spain)
- 12:15 Specific problems after war casualties  
Speaker to be confirmed

**10:45 - 12:45****Symposium: Interventional bronchoscopy in children**

**Aims:** At the end of the symposium participants will be able to:

- appreciate the classification and the patho-physiology of airway obstruction;
- describe the investigations to be used in the clinical assessment of children with airway obstruction;
- appreciate therapeutic strategies in children with airway obstruction;
- appreciate the clinical follow-up of infants who receive endoscopic treatment for airway obstruction.

**Target audience:** Paediatricians, neonatologists, paediatric pulmonologists and thoracic surgeons.

**Chairs:** F. Midulla (Rome, Italy), E. Eber (Graz, Austria)

- 10:45 Classification, patho-physiology and clinical assessment of airway obstruction in children  
S. Kotecha (Cardiff, United Kingdom)
- 11:15 Airway stents in children  
T. Nicolai (Munich, Germany)

- 11:45 Desobstruction methods for endobronchial airway stenoses: similarities and differences between children and adults  
C. Bolliger (Cape Town, South Africa)
- 12:15 Management of congenital long segment tracheal stenosis  
M. Elliott (London, United Kingdom)

10:45 - 12:45

### Symposium: Why is epigenetics important for lung disease?

**Aims:** The aim of this symposium is to inform the audience of emerging concepts regarding alterations in gene expression in lung disease.

**Target audience:** Clinicians, clinician scientists and basic research scientists.

**Chairs:** C. Taggart (Belfast, United Kingdom), C. Bingle (Sheffield, United Kingdom)

- 10:45 Introduction: what is epigenetics?  
M. Kabesch (Hannover, Germany)
- 11:15 Epigenetic modifications in idiopathic pulmonary fibrosis  
L. Pang (Nottingham, United Kingdom)
- 11:45 Histone Deacetylases (HDACs) and lung disease  
I. M. Adcock (London, United Kingdom)
- 12:15 DNA methylation and histone modifications of susceptibility in COPD and lung cancer  
I. Rahman (Rochester, United States of America)

10:45 - 12:45

### Hot Topic: Recent therapeutic advances with tyrosine-kinase inhibitors in non-small-cell lung cancer

**Aims:** The audience will learn about the emergence of a new type of drugs, the tyrosine-kinase inhibitors (TKI) in the management of lung cancer and the most recent clinical applications of TKI in the management of some advanced non-small cell lung cancer.

**Target audience:** Chest physicians and oncologists managing patients advanced NSCLC as well as all those who are interested by recent advances in the medical treatment of cancer.

- 10:45 TKIs: a new class of drugs in the management of lung cancer
- 11:15 Gefitinib for lung tumours with mutated EGF receptors
- 11:45 Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC
- 12:15 ALK inhibition with crizotinib

### MEET THE PROFESSOR SEMINARS

13:00 - 14:00

- **Meet the Professor: Cardiovascular disease in asthma and COPD**  
M. Cazzola (Rome, Italy)
- **Meet the Professor: Adenosine receptors and asthma**  
C. Page (London, United Kingdom)
- **Meet the Professor: Long-term weaning: nursing challenges**  
D. Field (London, United Kingdom)
- **Meet the Professor: Pre-operative pulmonary assessment**  
C. Bolliger (Cape Town, South Africa)
- **Meet the Professor: All that wheezes is not asthma**  
K. Guntupalli (Houston, United States of America)
- **Meet the Professor: Regulation of immune tolerance in the lung**  
C. Hawrylowicz (London, United Kingdom)

**CEREMONY****14:45 - 15:05****Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion)****followed by****15:05 - 16:45****“Pulmonary Hypertension in the Clinic Grand Round - an interactive session”****Aims:** The aim of this session is to provide a better insight in the differential diagnosis of pulmonary hypertension.**Target Audience:** Pulmonologists, radiologists, pathologists and nurses involved in the clinical care of pulmonary hypertension patients.

- 15:05 Diastolic left sided heart disease mimicking idiopathic PAH
- 15:30 Amyloid related pulmonary hypertension
- 15:55 Chronic thromboembolic pulmonary hypertension mimicking
- 16:20 Title to be confirmed: pulmonary veno-occlusive disease

**14:45 - 16:45****Symposium: New ERS Guidelines “Management of Work-Related Asthma”****Aims:** In this session, the ERS Guidelines “Management of Work-Related Asthma” will be presented. The aims of this symposium are to update knowledge and significantly improve practice in diagnostics, risk assessment, preventive strategies and treatment of occupational asthma. Evidence-based statements and recommendations related to five key questions will be presented.**Target audience:** Clinicians, occupational physicians and public health practitioners.**Chairs:** X. Baur (Hamburg, Germany), T. Aasen (Bergen, Norway)

- 14:45 What are the risk factors for a bad outcome of work-related asthma?  
P. Maestrelli (Padova, Italy)
- 15:15 How effective is controlling work-related exposures to prevent occupational asthma?  
D. Heederik (Utrecht, The Netherlands)
- 15:45 What is the yield and benefit of medical screening and medical surveillance of endangered workers?  
J. Rooijackers (Beuningen, The Netherlands)
- 16:15 What is the outcome of different management options?  
O. Vandenplas (Godinne, Belgium)

**14:45 - 16:45****Symposium: Non-tuberculous mycobacterial infections****Aims:** At the end of the symposium, attendees should be familiar with the clinical spectrum of nontuberculous mycobacterial (NTM) infections, special vulnerable populations, the diagnostic standards and the up-to-date therapeutic options.**Target audience:** Clinicians, clinical scientists, immunologists, microbiologists, specialist nurses and public health specialists involved in tuberculosis control, surveillance, care and research.**Chairs:** T. Aksamit (Rochester, United States of America), H. Milburn (London, United Kingdom)

- 14:45 Non-tuberculous mycobacteria in the environment and as human pathogens  
U. Greinert (Borstel, Germany)
- 15:15 Susceptibility to non-tuberculous mycobacteria infections  
A. Nieters (Freiburg, Germany)
- 15:45 Clinical spectrum of non-tuberculous mycobacterial infections  
J. Van Ingen (Nijmegen, The Netherlands)
- 16:15 Treatment of non-tuberculous mycobacteria infections  
D. Griffith (Tyler, United States of America)

**14:45 - 16:45****Symposium: Exercise strategies for chronic respiratory disease****Aims:** The aims of this session are to:

- understand the changes that occur within the peripheral muscle with increasing age and chronic respiratory disease;
- understand the basis for resistance exercise and what options are available to assess strength.

**Target audience:** Clinicians, physiologists, allied health professionals and nurses.**Chairs:** T. Troosters (Leuven, Belgium), M. Morgan (Leicester, United Kingdom)

- 14:45 Effect of aging on the peripheral muscle and the impact upon strength  
P. Aagaard (Odense, Denmark)
- 15:15 Rationale for endurance training: is the interval training the answer?  
I. Vogiatzis (Athens, Greece)
- 15:45 Voluntary and involuntary strength training regimes  
M. Sillen (Horn, The Netherlands)
- 16:15 Maintaining strength on the intensive therapy unit  
N. Hart (London, United Kingdom)

14:45 - 16:45

**Symposium: Molecular biomarkers at the bedside of critically ill patients****Aims:** The aims of this symposium are to:

- review studies of biomarkers with regard to its diagnosis and prognosis;
- discuss the attributes and pathogenetic relevance of molecular biomarkers needed to be clinical tools to assess the presence and activity of lung injury;
- review data on potential use of pharmacogenomics in predicting susceptibility and prognosis and in determining treatment options in sepsis.

**Target audience:** Pulmonologists, intensivists, immunologists, basic scientists, clinician, microbiologists, immunologists.**Chairs:** T. Welte (Hannover, Germany), S. Orfanos (Haidari, Greece)

- 14:45 Biomarker profiles in acute lung injury and acute respiratory distress syndrome  
J. Pugin (Geneva, Switzerland)
- 15:15 Biomarkers of early diagnosis and therapeutic response in ventilator-associated pneumonia  
A. Torres (Barcelona, Spain)
- 15:45 Are biomarkers helpful in sepsis for risk assessment or clinical trials?  
A. Artigas (Sabadell, Spain)
- 16:15 Genetic susceptibility to sepsis and acute lung injury  
J.-D. Chiche (Paris, France)

14:45 - 16:45

**Hot Topic: Mucus in airway diseases: bad or good partner?****Aims:** The origin of mucus in health and diseases, the failure of mucus clearance and the potential for new therapies aiming to reduce mucus formation or accelerate mucus clearance.**Target audience:** Clinicians (physicians, nurses, physiotherapists) and scientists dealing with airway diseases.

- 14:45 Hyperplasia of mucin-secreting epithelial cells: a remodelling feature of airway diseases
- 15:15 Regulation of mucus production in airway diseases
- 15:45 Does mucus protect or lead to epithelial colonisation and infection?
- 16:15 Targeting mucus as a new therapeutic avenue?

**EVENING SYMPOSIUM**

17:15 - 19:15

- **Reach, Treat, Benefit: The Value of Targeting Small Airways in Respiratory Disease**  
*Organised by Chiesi Farmaceutici SpA*
- **Therapeutic Options for PAH in 2011, the start of a new decade**  
*Organised by Eli Lilly and Company*

### Symposium: Non-CPAP therapies in obstructive sleep apnoea: report of the ERS Task Force group

**Aims:** The aims of this session are to:

- improve the knowledge on alternatives to continuous positive airway pressure (CPAP) therapy in sleep-disordered breathing (SDB);
- review evidence on efficient treatment options besides CPAP;
- identify patients to whom alternative methods can be recommended to demonstrate that critical selection of patients can improve outcome;
- evaluate the impact of the severity of the disease on the efficacy of these therapies.

**Target audience:** Clinicians, practitioners, health economists, healthcare scientists and sleep medicine scientists.

**Chairs:** J. Verbraecken (Antwerp, Belgium), W. Randerath (Solingen, Germany)

- 08:30 What can we expect from conservative therapy in obstructive sleep apnoea?  
B. Sanner (Wuppertal, Germany)
- 09:00 Oral appliances: a valid alternative for CPAP?  
M. Marklund (Umea, Sweden)
- 09:30 Velopharyngeal and nasal surgery: adjuvant or curative?  
A. Valipour (Vienna, Austria)
- 10:00 Hypopharyngeal surgery in obstructive sleep apnoea: can we rely on the current evidence?  
A. Boudewyns (Edegem, Belgium)

### Symposium: Heat, dust, smoke and ashes: anthropogenic and natural disaster disease epidemiology

**Aims:** The objective of this session is to educate clinicians in the way to handle disasters in the public health domain.

**Target audience:** Clinicians, epidemiologists and public health.

- 08:30 Disasters and respiratory health
- 09:00 The clinical findings in the shadow of the World Trade Center tragedy
- 09:30 The impact of heat wave and wild-fires on respiratory morbidity and mortality in Moscow. 2009
- 10:00 The Icelandic ash cloud and the air pollution that followed

### Symposium: From chronic lung diseases in childhood to COPD

**Aims:** This symposium will give an overview on lung development and the influence of premature birth on it, on chronic lung disease (CLD) of prematurity, and on long term respiratory effects. This symposium also will try to answer the question if CLD is the new COPD.

**Target audience:** Paediatricians, paediatric pulmonologists, neonatologists, fellows, nurses and respiratory physicians.

**Chairs:** L. Zimmermann (Maastricht, The Netherlands), K. Bohlin (Alvsjö, Sweden)

- 08:30 Normal lung development and its arrest after premature birth  
A. Hislop (London, United Kingdom)
- 09:00 Chronic lung disease of prematurity: an overview  
A. Jobe (Cincinnati, United States of America)
- 09:30 Consequences of chronic lung diseases for young adults  
E. Vrijlandt (Groningen, The Netherlands)
- 10:00 Chronic lung diseases and prematurity as risk factors for chronic obstructive pulmonary diseases  
O. Eickelberg (Munich, Germany)

### Symposium: New hope with the scope: upcoming endoscopic techniques

**Aims:** Based on the published literature the new techniques will be described and possible clinical indications will be presented and discussed.

**Target audience:** Clinicians, pulmonologists, surgeons, oncologists, general practitioners, residents and fellows.

**Chairs:** O. C. Burghuber (Vienna, Austria), M. Wahidi (Durham, United States of America)

- 08:30 Optical coherence tomography  
A. Ernst (Brighton, Ma, United States of America)
- 09:00 Playing with the wave length: autofluorescence endoscopy and narrow band imaging  
R. Eberhardt (Heidelberg, Germany)
- 09:30 Endocytoscopy  
P. Shah (London, United Kingdom)

- 10:00 NOTES, or natural orificium total endoscopic surgery  
F. Herth (Heidelberg, Germany)

08:30 - 10:30

### Symposium: The modern pulmonologist consultant in a general hospital: the importance of an holistic approach

**Aims:** Modern pulmonologists and clinicians must act synergistically with other specialists and must take a holistic approach to the "complex patient".

**Target audience:** Clinicians, physicists

- 08:30 Diagnosis and treatment of asthma and COPD during pregnancy  
09:00 Pulmonary-renal interaction. Pulmonary involvement in kidney diseases  
09:30 Pulmonologist-rheumatologist interaction in connective tissue diseases  
10:00 Endocrinological diseases and the lung

10:45 - 12:45

### Symposium: Treating advanced emphysema

**Aims:** Based on the published literature the new techniques will be described and possible clinical algorithms will be presented and discussed.

**Target audience:** Clinicians, pulmonologists, surgeons, oncologists, general practitioners, residents and fellows.

**Chairs:** C. Marquette (Nice, France), D. Van Raemdonck (Leuven, Belgium)

- 10:45 Pharmacological lung volume reduction: how much can you achieve?  
K. F. Rabe (Großhansdorf, Germany)  
11:15 Endoscopic lung volume reduction: does it really work?  
D. Gompelmann (Heidelberg, Germany)  
11:45 Lung volume reduction surgery: for whom?  
W. Weder (Zurich, Switzerland)  
12:15 Lung transplantation: who benefits most?  
M. Iversen (Copenhagen, Denmark)

10:45 - 12:45

### Symposium: Lung cancer management in the elderly

**Aims:** At the end of the symposium, the audience will have the best knowledge of the strategies for elderly patients.

**Target audience:** Clinician, surgeons, radiotherapists, oncologists.

**Chairs:** F. Gamarra (Munich, Germany), H. Lena (Rennes, France)

- 10:45 Assessing the elderly patient with lung cancer  
H. Le Caer (Draguignan, France)  
11:15 What are the specificities of radiotherapy for elderly patients?  
P. Van Houtte (Brussels, Belgium)  
11:45 Medical treatment and the capacity to deliver multimodality treatment in elderly patients  
A. Pallis (Chios, Greece)  
12:15 Surgery in older patients with lung cancer: the old but fit elderly  
M. Paul (Amsterdam, The Netherlands)

10:45 - 12:45

### Symposium: Obesity and the lung

**Aims:** The aims of this symposium are to:

- describe the impact of increasing obesity on the respiratory system
- describe the nutritional management of the obese patient with respiratory disease
- describe interventions that may support weight reduction in the obese patient

**Target audience:** Clinicians, physicians, thoracic surgeons, physiologists physiotherapists and other and allied health professionals

- 10:45 Effect of obesity on the healthy lung and in chronic respiratory disease  
11:15 Nutritional management of the obese patient with chronic respiratory disease  
11:45 Rehabilitation and exercise for the obese patient with COPD  
12:15 Bariatric surgery for patients with chronic respiratory disease



**Hot Topic: Exhaled biomarker profiles in paediatric respiratory disease: from bench to bedside?**

**Aims:** After this session, the participants will:

- understand the concept of integrative analysis of high-dimensional biomarker profiles
- have an overview of the 'omics' technologies applied to exhaled air
- appreciate the potential and feasibility of these techniques in respiratory disease in childhood.

**Target audience:** Clinicians (paediatric and adult) and scientists (academic and industrial).

- 08:30 Use of exhaled breath condensate in childhood: challenges and pitfalls  
09:00 Metabolomics: a new frontier for research in respiratory medicine  
09:30 Electronic nose and wheezing in young children  
10:00 The role of biomarker profiles in cystic fibrosis